COVID-19 pandemic and healthcare utilization in ovarian cancer patients
Despite a shift from office visits to virtual visits during COVID-19, no differences in laboratory monitoring of chemotherapy and no increase in ER visits and hospitalizations were observed in ovarian cancer patients.
Authors
- Matthew Monberg (ORCID: https://orcid.org/0009-0006-7462-4782)
- Chun Chao (ORCID: https://orcid.org/0000-0002-6072-4954)
- Natalie L. Ayoub (ORCID: https://orcid.org/0000-0003-2931-5834)
- Melissa Hodeib
- Elizabeth A. Szamreta (ORCID: https://orcid.org/0000-0001-7723-3388)
- Kimberly L. Cannavale (ORCID: https://orcid.org/0000-0003-3892-9686)
- Lanfang Xu
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- White Memorial Medical Center (US)
- Kaiser Permanente (US)
- Kaiser Permanente Riverside Medical Center (US)
- Applied Optoelectronics (United States) (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1016/j.gore.2025.102019
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00